Patent reform will pass soon [?]
A Feb. 8 piece in Reuters suggests that there will be patent reform:
High tech companies and drug companies agree that U.S. patent reform will pass soon, but there is considerably less agreement on what it should look like.
As might be expected, the significant disagreement concerns a money issue:
Tom DiLenge, general counsel for the Biotechnology Industry Organization, has called calculating damages for infringement "the toughest nut to crack."
The article even quoted a pharma person as seeing a consensus coming:
Philip Johnson, chief patent counsel for Johnson & Johnson, predicted the two sides would get a consensus on the bill, despite the widely differing interests involved.
High tech companies and drug companies agree that U.S. patent reform will pass soon, but there is considerably less agreement on what it should look like.
As might be expected, the significant disagreement concerns a money issue:
Tom DiLenge, general counsel for the Biotechnology Industry Organization, has called calculating damages for infringement "the toughest nut to crack."
The article even quoted a pharma person as seeing a consensus coming:
Philip Johnson, chief patent counsel for Johnson & Johnson, predicted the two sides would get a consensus on the bill, despite the widely differing interests involved.
posted by Lawrence B. Ebert at 4:42 PM
0 Comments:
Post a Comment
<< Home